Related Experiment Videos
Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
E M Bruckheimer1, S Brisbay, D J Johnson
1Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, TX 77030, USA.
Oncogene
|November 15, 2000
Summary
The proto-oncogene bcl-2 accelerates prostate cancer development in mice by increasing cell proliferation and reducing cell death. This study reveals bcl-2
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer pathogenesis involves complex genetic and molecular alterations.
- The role of the bcl-2 proto-oncogene in cancer progression is a key area of research.
- Transgenic mouse models are crucial for studying cancer development in vivo.
Purpose of the Study:
- To investigate the impact of bcl-2 proto-oncogene expression on prostate cancer pathogenesis and progression.
- To evaluate the combined effects of bcl-2 and SV40 early genes (T/t antigens) in a transgenic mouse model.
Main Methods:
- Generation of double transgenic mice (probasin-bcl-2 X TRAMP F1 [BxT]) by crossing probasin-bcl-2 mice with TRAMP mice.
- Evaluation of prostate size, cell proliferation, apoptosis, tumor formation latency, incidence, and metastasis.
- Assessment of hormone-independent prostate cancer incidence.
Main Results:
- BxT mice showed increased prostate wet weight, linked to increased proliferation (T/t antigens) and decreased apoptosis (bcl-2).
- Tumor formation latency was reduced in BxT mice compared to TRAMP mice.
- Metastasis incidence was similar, but hormone-independent prostate cancer incidence was reduced in BxT mice.
Conclusions:
- The proto-oncogene bcl-2 facilitates multistep prostate carcinogenesis in vivo.
- bcl-2 overexpression contributes to prostate cancer progression by modulating cell proliferation and apoptosis.
- This model provides insights into the genetic drivers of prostate cancer development.